Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus DECLOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus DECLOMYCIN.
ACTICLATE CAP vs DECLOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic